^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

XY0206

i
Other names: XY0206
Company:
Shijiazhuang Yiling Pharma
Drug class:
FLT3 inhibitor
Related drugs:
1year
A Phase I/II Trial of the FLT3 Kinase Inhibitor XY0206 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (ASH 2023)
XY0206 is a novel FLT3 inhibitor that showed a good safety profile, a potent anti-leukemic activity and improved efficacy in patients with FLT3mut+ R/R AML.
Clinical • P1/2 data
|
FLT3 (Fms-related tyrosine kinase 3)
|
FLT3-ITD mutation • FLT3 mutation • FLT3 positive
|
XY0206
over1year
New P3 trial
|
FLT3 (Fms-related tyrosine kinase 3)
|
FLT3-ITD mutation
|
cytarabine • azacitidine • XY0206
over1year
A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
P1, N=60, Recruiting, Shijiazhuang Yiling Pharmaceutical Co. Ltd | Trial completion date: Dec 2022 --> Feb 2024 | Trial primary completion date: Jul 2022 --> Feb 2024
Trial completion date • Trial primary completion date
|
XY0206
over4years
A Study of XY0206 in Subjects With Advanced or Metastatic Solid Tumours (clinicaltrials.gov)
P1, N=34, Recruiting, Shijiazhuang Yiling Pharmaceutical Co. Ltd | Not yet recruiting --> Recruiting
Clinical • Enrollment open
|
KDR (Kinase insert domain receptor)
|
XY0206